Objective: To characterize the neuropathologic features of neuromyelitis optica (NMO) at the medullary floor of the fourth ventricle and area postrema. Aquaporin-4 (AQP4) autoimmunity targets this region, resulting in intractable nausea associated with vomiting or hiccups in NMO.
present with intractable vomiting as the first and isolated symptom of NMO are usually evaluated by gastroenterologists and neurologic evaluation is often not pursued. 9 Area postrema, the emetic reflex center, 12 is comprised of 2 symmetric structures at the floor of the rhomboid fossa. Like other circumventricular organs (CVO), it consists of loose tissue containing glia and neurons, has a thin ependymal cover, and is penetrated by convoluted capillaries that lack tight endothelial junctions forming a permeable bloodbrain barrier (BBB). 12, 13 Area postrema is connected to hypothalamic and brainstem nuclei regulating fluid balance, osmoregulation, immunomodulation, and other important physiologic systems. 12, 14 Like other periventricular areas, the medullary floor of the fourth ventricle and area postrema express AQP4 abundantly and are thus preferential targets for NMO lesions. 3, 4, 8, 15 Expectedly, clinical manifestations of NMO include intractable nausea/vomiting/hiccups. This study is the first to thoroughly characterize the neuropathology of NMO lesions involving the area postrema and the medullary floor of the fourth ventricle. These lesions presumably represent the pathologic substrate for the intractable but reversible nausea and vomiting that occur in NMO.
METHODS Archival material. To characterize the NMO neuropathology at the medullary floor of the fourth ventricle and area postrema, we analyzed microscopic transverse sections of the caudal medulla in archival autopsy tissue from 15 clinically and pathologically confirmed NMO cases, 5 MS control cases (4 acute and 1 chronic), and 8 neurologically normal controls. Autopsies were performed at Mayo Clinic, Rochester, MN, or submitted from other institutions for diagnostic purposes between 1958 and 2009. This study was approved by the Mayo Clinic Institutional Review Board. Clinical follow-up blinded to pathologic outcome was obtained via review of medical records. All 15 cases included in the pathologic NMO cohort met Wingerchuk criteria for NMO or NMO spectrum disorder (NMOSD), 1 and exhibited NMO-characteristic histopathologic optic or spinal lesions. 5, 8 The characteristics of this cohort are listed in table e-1 on the Neurology ® Web site at www.neurology.org. Median age was 45 years at symptom onset (range 12-74) and 48.5 years at death (range 16 -79). Median disease duration was 36 months (range 8 -108). NMO-IgG serostatus was known in 6 cases (positive in 5, including all 3 NMOSD cases).
Neuropathologic evaluation and immunohistochemistry. Specimens were fixed in 10%-15% formalin and embedded in paraffin. Sections were stained with hematoxylin & eosin (H&E) to demonstrate morphology of tissues and cells and Luxol fast blue/periodic acid-Schiff to demonstrate myelin and myelin degradation products. Immunohistochemistry was performed using an avidin-biotin or alkaline phosphatase/antialkaline phosphatase technique without modification and primary antibodies specific for AQP4, myelin proteolipid protein, glial fibrillary acidic protein (GFAP), neurofilament, all T (CD3), cytotoxic T (CD8), and B (CD20) lymphocytes, plasma cells (CD138), macrophages/microglia (KiM1P), and activated complement (C9neo) (table e-2). 8 Inflammatory infiltrates were characterized with respect to their presence or absence, character (diffuse parenchymal/focal perivascular), and severity (mild, moderate, marked) and graded on the basis of inflammatory cell cuff thickness as follows: absent, mild (few vessels with 1 partial or complete cuff), or moderate to marked (many vessels with 1 cuff or few vessels with 2 cuffs, or few to many vessels having Ͼ3 cuffs).
Statistical analysis. We used Wilson confidence intervals
(CI) to estimate proportions and 95% CIs and logistic regression to evaluate whether the presence of lesions at the level of the medullary floor of the fourth ventricle and area postrema increased the odds of a patient with NMO having an episode with nausea/vomiting. Confidence intervals for the odds ratio (OR) of nausea/vomiting given the presence vs absence of NMO lesions at this level were calculated using the profile likelihood method. The statistical analysis was performed using R software version 2.8.1. No specimen had evidence of viral or autoimmune encephalitis, ischemic stroke, Balo lesions, or other superimposed pathology that could explain the focal loss of AQP4 at this level. 8, 16, 17 Table 1 lists the pathologic characteristics of NMO lesions in this region. Most lesions selectively involved lateral aspects of the ventricular floor including the area postrema bilaterally, and extended ventrally into the medullary tegmentum ( figure 1 , A, C, D, and figure e-1, A-C). In only a single case, AQP4 loss also extended into the median aspect of the ventricular floor around the obex. 8 Lesions were confined to the medullary floor of the fourth ventricle and area postrema and did not represent rostral extensions of cervical myelitis or dorsal extensions of ventral medullary lesions. Only one patient with area postrema AQP4 loss (patient 1 in table 1) showed the presence of a median ventral medullary lesion that extended dorsally to the level of the retro-olivary sulcus, but did not reach the ventricular floor. No other NMO medulla with AQP4 loss at the level of the ventricular floor and area postrema demonstrated additional medullary lesi-ons (table 1). As previously reported, AQP4 immunoreactivity in control (normal and MS) and nonlesional NMO medullae was most intense in subependymal regions at the floor of the fourth ventricle, and was localized to astrocytic end-feet abutting blood vessels and neurons, and to basolateral membranes of ependymal cells ( figure 1 , A, C, D, and figure e-1, A-C). 8 AQP4 immunoreactivity was clearly evident in the area postrema in MS and healthy control tissues, as well as in nonlesional NMO medullae (manifested by AQP4ϩ and GFAPϩ astrocytic end-feet surrounding the basolateral endothelial membranes and neurons), but was less intense than in the remainder of the medullary ventricular floor ( figure 1 In 5 of 6 cases, AQP4 loss areas exhibited tissue rarefaction or vacuolation and blood vessel wall thickening ( figure 2A ). Three cases exhibited perivascular complement deposition (figures 2E and 4J). Complement products were also found in macrophages and reactive distended astrocytes (figures 2E and 3C). No acute neuronal pathology was found. Because area postrema contains unmyelinated axons, the presence or absence of demyelination at this site could not be assessed. However, as previously reported, 8 myelin and axons were preserved in areas of AQP4 loss extending from the floor of the fourth ventricle into the dorsal medullary tegmentum and myelin-laden macrophages were rarely observed. All 6 cases with focally lost or reduced AQP4 contained moderate to marked parenchymal and perivascular inflammation. Clinical episodes of nausea and vomiting. Blinded retrospective review of the patients' clinical histories revealed documentation of nausea/vomiting episodes in 4 of the 6 patients with area postrema lesions (table e-1). In 3 patients, the episode occurred within 2 months of death. In one patient, it occurred as a relapse during established disease. Clinical information was limited in the other 2 cases. Among the 9 patients without lesions at this level, only one had a documented episode of nausea/vomiting as initial disease presentation. Based on a logistic regression model with pathologic involvement of the medullary floor of the fourth ventricle and area postrema as the predictor and nausea/vomiting as the event, the odds of nausea/vomiting symptoms being present were an estimated 16 times greater with presence vs absence of lesions at this level (95% CI 1.43-437; p ϭ 0.02).
RESULTS

DISCUSSION
In contrast to MS, intractable nausea/vomiting/hiccups is a characteristic symptom of NMO often preceding optic neuritis or transverse myelitis 10, 11 and may occur as an isolated clinical manifestation of early disease. 9 Our study demonstrates pathologic abnormalities in the caudal medullae at the floor of the fourth ventricle and area postrema in 40% of patients with NMO. This frequency corresponds to the incidence of documented clinical episodes of intractable nausea/vomiting/hiccups in NMO. 10, 11 The occurrence of nausea/vomiting was overrepresented among patients with NMO with lesions in this region (67%) compared to patients with NMO without lesions (11%). The presence of these lesions increased the odds of nausea/ vomiting 16 times (95% CI 1.43-437, p ϭ 0.02). Thus, despite selection, ascertainment, and other biases inherent in neuropathologic studies, it would be unlikely that the effect was smaller than a 43% increase in the odds and it could be higher than a 16fold increase. Selective loss of AQP4 was the unifying neuropathologic characteristic of all NMO lesions found in the medullary floor of the fourth ventricle and area postrema. This was accompanied by tissue rarefaction, inflammation, variable complement deposition, and nonlytic alterations in GFAP-positive reactive astrocytes. As previously reported, lesions at this level were nondestructive with relative neuronal, axonal, and myelin preservation. 8 All 6 NMO cases exhibited AQP4 loss from the area postrema and lateral regions of the medullary ventricular floor. Only one case also had midline involvement. 8 These histopathologic findings suggest that area postrema may be a preferential and selective target of the NMO disease process, and are compatible with clinical reports of nausea/vomiting preceding episodes of optic neuritis and transverse myelitis 10, 11 and even representing the heralding disease symptom. 9 MRI also had demonstrated isolated involvement of the area postrema in NMO. 9 Pathologic involvement of the area postrema independently of the fourth ventricle floor further supports the involvement of this region as a potential site of initial NMO-IgG entry into the CNS. In common with other CVO, the area postrema lacks tight endothelial cell junctions, 12, 13 and neural cells in this region are readily accessible to circulating IgG. 18 Furthermore, the area postrema is one of the most vascularized brain regions. Its plasma flow and surface area/permeability ratio are higher than adjacent medullary regions. Slowing of blood flow by specialized pericapillary "pools" of interstitial fluid in the area postrema increases the exposure of local neurons and glia to bloodborne constituents. 13 The endothelial permeation of NMO-IgG and its delayed clearance may summate to maintain an exceptionally high concentration around astrocytic end-feet at this site, thus enhancing the vulnerability of area postrema to AQP4-IgG-induced pathophysiology. The selective bilateral involvement of the area postrema in 5/6 NMO cases suggests that IgG targeting AQP4 at this site might be sufficient to initiate the NMO disease process without requiring antigen-specific T-cells to breach the BBB. This suggestion is supported by the reported passive transfer of "essential hypernatremia" to mice by an IV injected human autoantibody targeting the sodium-level sensing Na x channels expressed in astrocytes, ependymal cells, and pituicytes in the CVO. 19, 20 Previous reports of NMO pathology emphasized astrocyte necrosis and GFAP loss secondary to the complement-mediated lysis that follows AQP4-IgG binding. [21] [22] [23] By contrast, area postrema lesions were characterized by a prominent nonlytic reaction of GFAP-positive astrocytes. The medullary ventricular floor and area postrema contained an abundance of uninucleated and binucleated reactive astrocytes, some having multiple, elongated, thin processes. Despite AQP4 loss, they retained GFAP-positive foot processes, suggesting that complement-mediated cytotoxicity in this region is minimized by rapid and persistent downregulation of AQP4. 24 The appearance of the astrocytes was reminiscent of cultured astrocytes in which AQP4 reduction by RNAi treatment was accompanied by transformation from polygonal to elongated morphology, interpreted as a cell strategy to increase surface/volume ratio to maintain water flux in the absence of AQP4. 25 The nonlytic lesions containing intact GFAPpositive reactive astrocytes that we identified in the medullary floor of the fourth ventricle and area postrema contrast with the destructive demyelinating NMO lesions found in the same patients' spinal cords or optic nerves. 5, 8 It is conceivable that perivascular astrocytes in the area postrema may have unique properties. Regional differences in complement-regulatory protein expression are known to determine vulnerability to autoantibodyinduced complement-mediated damage in different regions of the nervous system. 26 Complementregulatory proteins in the plasmalemma of area postrema astrocytes may therefore render them resistant to lysis by complement. 27 Additional studies are needed to confirm if this is the case for NMO. In the absence of astrocytic lysis, IgG-mediated crosslinking of AQP4 in the area postrema may trigger reactive astrocytosis. In Trypanosoma brucei infection, 19 another immune-mediated CVO disorder, reactive astrocytes in the area postrema respond as innate immune effectors, producing chemokines and cytokines that recruit and activate eosinophils, macrophages, and lymphocytes. Indeed we have observed in NMO analogous recruitment of perivascular macrophages, eosinophils, and pronounced activation of parenchymal microglia. Factors released from reactive astrocytes in the area postrema can activate neighboring cells to further skew and amplify the immune response, enhance BBB permeability, and attract granulocytes and monocytes from the systemic circulation. 27 Products of early-cleaved complement components, as well as cytokines and chemokines produced by the reactive astrocytes, would also activate resident microglia and dendritic cells. 27, 28 Inflammatory cytokine signaling from area postrema microglia, macrophages, and dendritic cells spreads to microglia in adjacent brainstem nuclei as a volume transmission signal. Diffusion, relayed by intermediate molecules, propagates the signal throughout the brain parenchyma by recruiting adjacent microglia. 29 Because the ependymal lining of the area postrema does not form a tight blood-CSF barrier, 30 cytokines released therein can access the CSF to influence distant brain structures. 31 CSF is also another potential pathway for NMO-IgG to spread from the area postrema to distant brain regions. 32 Additionally, immune cells in area postrema are known to activate area postrema sensory neurons. 28 Projections from area postrema to adjacent brainstem and hypothalamic nuclei are responsible for the emetic reflex but also for the sympathetic nervous system and hypothalamo-pituitary-adrenal axis activation which may modulate the cytokine-induced sickness behavior, immune response, or brain water homeostasis. 12, 14, 20 It remains unclear why symptomatic pathophysiology at the level of the medullary floor of the fourth ventricle and area postrema is not a universal NMO pathologic hallmark. A plausible explanation is that the reversibility of these inflammatory nondestructive medullary lesions may reflect a transient functional impairment of the astrocyte to mediate water flux that is rapidly compensated in AQP4-enriched regions. 8 This is supported by clinical data showing that patients with NMO can recover spontaneously from intractable episodes of nausea/vomiting [9] [10] [11] and by imaging data describing rapid resolution of such NMO medullary lesions. 3, 4, 9, 10 Furthermore, AQP4 and excitatory amino acid transporter 2 (EAAT2) exist in astrocytic membranes as a macromolecular complex and binding of NMO-IgG to AQP4 downregulates both AQP4 and EAAT2 resulting in impaired glutamate homeostasis. 21 However, whereas EAAT2 is heavily expressed in the central spinal cord, the area postrema lacks EAAT2. 21, 33 The concomitant loss of both AQP4 and EAAT2 in the spinal cord in the context of NMO attacks, resulting in glutamate-mediated tissue injury, might account for the occurrence of NMO destructive central spinal cord lesions. 8, 21 The fact that the area postrema is not dependent on EAAT2 to regulate glutamate homeostasis could also explain why area postrema NMO lesions are nondestructive as well as clinically and radiographically reversible.
Why is nausea/vomiting not a universal NMO symptom? First, nausea/vomiting are overlooked in the context of NMO, especially as the initial isolated symptoms. 9 Second, other CVO could serve as initial points of attack. Hypothalamic involvement has been described in NMO. 34 An initial episode at the level of the organum vasculosum of lama terminalis would present with fever episodes reflecting NMO-IgG binding-induced cytokine action at the level of hypothalamus 35 or with hypothermia in the more advanced settings of destructive NMO hypothalamic lesions. 34, 36 Febrile episodes have been described preceding NMO exacerbations and even as initial presenting NMO symptoms 11 but they have been attributed to viral infections. Third, autoantibodies must enter or be locally synthesized in sufficient concentrations to be pathogenic in the CNS. Nausea/ vomiting has been documented in some patients at the peak of their NMO-IgG titer. 11 However, when the NMO-IgG serum concentration is not high enough to cause glial activation and neuronal impairment in the CVO, astrocytes and endothelial cells could be affected by proinflammatory cytokines released in response to bacterial or viral infections 37 and, in such instances, NMO-IgG would enter the CNS through a diffusely disrupted BBB.
We have documented unique neuropathologic features of NMO lesions at the level of the medullary floor of the fourth ventricle and area postrema. These lesions are distinct from NMO lesions in other CNS regions by being inflammatory, nondestructive, and nondemyelinating and likely represent the pathologic substrate for the intractable but reversible nausea/vomiting that sometimes occur in NMO. Our observation that area postrema astrocytes appear to resist complement-mediated lysis suggests that IgG-induced crosslinking of AQP4 may activate an orchestrated astrocytic inflammatory response that can be propagated through the CNS astrocytic network, thus enhancing BBB permeability, NMO-IgG entry in other brain regions, and recruitment and activation of leukocytes that further exacerbate and propagate the disease pathology. The novel characteristics that we have documented in NMO lesions involving the medullary floor of the fourth ventricle and area postrema further distinguish NMO from MS pathologically. 
